Plain-English translation of NCT06730672 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications — Voronib and Everolimus — for people with advanced kidney cancer whose previous immunotherapy treatments have failed. Both medications work by blocking different signals that help cancer cells grow. Researchers want to see if taking them together is safe and effective for patients like you who have already tried other treatments.
When immunotherapy doesn't work against kidney cancer, patients need other options. This medication combination targets cancer cells in different ways, which might help when standard immunotherapy approaches have stopped working.
You likely qualify if…
You likely don't qualify if…
You would take two pills by mouth once daily — one Voronib tablet and one Everolimus tablet. The study involves regular visits to check your health, including blood tests and imaging scans to see how your cancer is responding. You would continue this treatment as long as it is helping and you are tolerating it well. The trial expects to enroll about 80 people total and is actively recruiting now.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China